PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. Ito T, Okamoto I, Tokashiki K, Sato H, et al. Anticancer Res 2022;42:1547-1554.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ito T, Okamoto I, Tokashiki K, Sato H, et al. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. Anticancer Res 2022;42:1547-1554.
PMID: 35220251